SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), reported the sale of 4,000 shares of common stock over two consecutive days, according to a recent SEC filing. The company, currently valued at $937 million, has received a "FAIR" overall financial health rating from InvestingPro. The transactions, executed under a Rule 10b5-1 trading plan, took place on January 16 and 17, with shares sold at prices ranging from $10.60 to $11.93. The total value of these sales amounted to $42,860. Following these transactions, Ma Songjiang retains an indirect ownership of 2,907,138 shares, held by a spouse. The stock, which currently trades at $10.96, appears slightly overvalued according to InvestingPro Fair Value metrics. InvestingPro analysis reveals the company operates with moderate debt levels and maintains strong liquidity, with current assets exceeding short-term obligations by 3.7x.
In other recent news, Gyre Therapeutics has made significant changes in its leadership, with the appointment of Ping Zhang as the lead independent director of its Board of Directors. Zhang brings a wealth of financial experience from his current role as a Managing Partner at String Capital Management and previous positions at AEON Life Insurance (NSE:LIFI) Company and Japan Asia Investment Co. Additionally, Gyre Therapeutics announced changes at its subsidiary, Gyre Pharmaceuticals, with Ying Luo stepping down as Chairman to allow Songjiang Ma to take the helm.
These developments come as Gyre Therapeutics continues its focus on the development and commercialization of its drug F351. Furthermore, Gyre Pharmaceuticals is advancing its pipeline in China, including ongoing clinical trials for F351 and the commercialization of ETUARY®, a leading treatment for idiopathic pulmonary fibrosis, which reported net sales of $112.1 million in 2023. The company reported total revenues of $105.03 million in the last twelve months, highlighting a strong gross profit margin of 96.23%.
Analysts from InvestingPro have noted the company maintains strong liquidity with a current ratio of 3.72, despite operating with moderate debt levels. These recent developments and financial indicators are important to consider for investors interested in Gyre Therapeutics' performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.